Trials Sponsors Conditions Drugs Pricing

Conditions

Atrial Fibrillation Atrial Flutter

Keywords

Atrial FibrilationAntithrombotic therapyAtrial Flutter

Outcome Measures

Primary Outcomes (12)

INR control rate
12 months
Oral anticoagulation discontinuation rate
12 months
Percentage of death
12 months
Percentage of stroke
12 months
Percentage of systemic embolism
12 months

Interventions

Patient Registry DataOther

To set data on demographic characteristics,documenting antithrombotic therapy, describe the INR control level of VKA users, discontinuation rates and clinical outcomes, such as stroke, hemorrhage and death.

Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.

Eligibility Criteria

Age18 Years+

Sexall

Healthy VolunteersNo

Age GroupsAdult (18-64), Older Adult (65+)

Sampling MethodProbability Sample

Study Population

Patient with Atrial Fibrilation or Atrial Flutter

You may qualify if:

Age \> 18 years-old that signed informed consent;

Sponsors & Collaborators

Brazilian Clinical Research Institute
Otherlead

Study Sites (17)

Hospital Interzonal General de Agudos "Dr. José Penna"

Bahía Blanca, Buenos Aires, Argentina

DIM Clínica Privada

Ramos Mejía, Buenos Aires, Argentina

Centro de Investigaciones Medicas Temperley (CIMeT)

Temperley, Buenos Aires, Argentina

Hospital Italiano de La Plata

Buenos Aires, La Plata, Argentina

Centro Modelo de Cardiologia

San Miguel de Tucumán, Tucumán Province, Argentina

Centro Medico Luquez

Córdoba, Argentina

Prevención Cardiovascular Salta

Salta, Argentina

Related Publications (1)

de Barros E Silva PGM, Damiani L, Arantes PE, Ianof JN, Yoshida LAF, Barbosa LM, Gomez-Mesa JE, Bahit MC, Padilla FG, Dall'Orto FTC, de Los Rios Ibarra MO, Antunes M, Sanchez AO, Cartasegna L, Tramujas L, Dos Reis Saraiva Falcao SN, Hominal M, Gamba MAA, de Lima CEB, Venancio AC, Montenegro E, Muntaner JA, Almagro SM, Troiani do Nascimento C, Carneiro RM, Montana OR, Lopes RD. Registry of atrial fibrillation in Latin America: Primary results of the LACROSS study. Am Heart J. 2026 Nov;301:107514. doi: 10.1016/j.ahj.2026.107514. Epub 2026 Jun 19.
PMID: 42320706DERIVED

MeSH Terms

Conditions

Atrial FibrillationAtrial Flutter

Condition Hierarchy (Ancestors)

Arrhythmias, CardiacHeart DiseasesCardiovascular DiseasesPathologic ProcessesPathological Conditions, Signs and Symptoms

Study Officials

Renato D. Lopes, MD, PhD
Instituto Brasileiro de Pesquisa Thomaz de Carvalho - BCRI
STUDY CHAIR

Enrollment

2,016 participants (actual enrollment reported by the registry).

Study Design

Study Type: observational
Observational Model: COHORT
Time Perspective: PROSPECTIVE
Target Duration: 12 Months
Sponsor Type: OTHER
Responsible Party: SPONSOR

Study Record Dates

First Submitted

June 23, 2020

First Posted

July 7, 2020

Study Start

August 4, 2020

Actual (reported)

Cardiovascular Registry of Atrial Fibrillation

Brief Summary

Registry Overview

Trial Relationships

Study Timeline

First Submitted

First Posted

Study Start

Primary Completion

Study Completion

Conditions

Keywords

Outcome Measures

Primary Outcomes (12)

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (17)

Related Publications (1)

MeSH Terms

Conditions

Condition Hierarchy (Ancestors)

Study Officials

Enrollment

Study Design

Study Record Dates

You may not qualify if:

Data Sharing

Source record

Locations

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

First Submitted

First Posted

Study Start

Primary Completion

Study Completion

Conditions

Keywords

Outcome Measures

Primary Outcomes (12)

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (17)

Related Publications (1)

MeSH Terms

Conditions

Condition Hierarchy (Ancestors)

Study Officials

Enrollment

Study Design

Study Record Dates

You may not qualify if:

Data Sharing

Source record

Locations